Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
Merck snags Chinese cancer drug for up to US$3.3 billion
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million upfront, plus as much as US$2.7 billion in milestone payments. Read more at The Business Times.
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,
Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.
pharmaphorum2h
MSD joins PD-1/VEGF push in cancer with LaNova deal
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
BioPharma Dive22m
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
FierceBiotech2h
Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...
pharmaphorum1d
FDA won't back Lilly's PD-1 antibody based on Chinese data alone
There has been expectation that the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC treatment, offering an ...
BioPharma Dive1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Yahoo Finance7d
OncoResponse Announces Phase 1 Results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
a fully human IgG1 antibody that binds specifically to LILRB2. OR502 will be administered as a monotherapy and in combination with anti-PD-1, cemiplimab, in subjects with advanced solid tumors.
manilatimes1h
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has received IND approval for two clinical ...
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...
Hosted on MSN3d
Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours
"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...